TY - JOUR
T1 - Prognostic significance of YWHAZ expression in localized prostate cancer
AU - Rüenauver, K.
AU - Menon, R.
AU - Svensson, M. A.
AU - Carlsson, J.
AU - Vogel, W.
AU - Andrén, O.
AU - Nowak, M.
AU - Perner, S.
N1 - Funding Information:
This work was supported by grants from the Wilhelm Sander Foundation (2011.077.1), the Rudolf-Becker-Foundation and the German Research Foundation (Deutsche Forschungsgemeinschaft (DFG), Emmy-Noether-Program, PE1179/2-1) to SP. Furthermore, the project was supported by the medical student research grant of the Medical Faculty of the University of Bonn (BONFOR) to KR.
Publisher Copyright:
© 2014 Macmillan Publishers Limited.
Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2014/12/13
Y1 - 2014/12/13
N2 - Background:Prostate cancer (PCa) patients are often over-treated because of the lack of biomarkers needed to distinguish the lethal from the indolent form of PCa. YWHAZ was recently identified as a potential therapeutic target in castration-resistant PCa (CRPC). Therefore, this study focused on determining the prognostic significance of YWHAZ in localized PCa.Methods:YWHAZ expression was assessed by immunohistochemistry on formalin-fixed paraffin-embedded tissue from 213 men who underwent radical prostatectomy. Kaplan-Meier analysis and Cox proportional-hazards models were used to assess the prognostic value of YWHAZ intensity.Results:High YWHAZ expression was strongly associated with high Gleason score at the time of diagnosis (P<0.001) and PSA relapse (P=0.001). Importantly, patients with high expression of YWHAZ had a higher risk of CRPC development (P=0.002) and reduced survival time (P=0.002).Conclusions:Our findings indicate that YWHAZ could serve as a promising prognostic biomarker in localized PCa to predict poor prognosis and to identify a subgroup of tumors, which might benefit from earlier adjuvant or YWHAZ-targeted therapy.
AB - Background:Prostate cancer (PCa) patients are often over-treated because of the lack of biomarkers needed to distinguish the lethal from the indolent form of PCa. YWHAZ was recently identified as a potential therapeutic target in castration-resistant PCa (CRPC). Therefore, this study focused on determining the prognostic significance of YWHAZ in localized PCa.Methods:YWHAZ expression was assessed by immunohistochemistry on formalin-fixed paraffin-embedded tissue from 213 men who underwent radical prostatectomy. Kaplan-Meier analysis and Cox proportional-hazards models were used to assess the prognostic value of YWHAZ intensity.Results:High YWHAZ expression was strongly associated with high Gleason score at the time of diagnosis (P<0.001) and PSA relapse (P=0.001). Importantly, patients with high expression of YWHAZ had a higher risk of CRPC development (P=0.002) and reduced survival time (P=0.002).Conclusions:Our findings indicate that YWHAZ could serve as a promising prognostic biomarker in localized PCa to predict poor prognosis and to identify a subgroup of tumors, which might benefit from earlier adjuvant or YWHAZ-targeted therapy.
UR - http://www.scopus.com/inward/record.url?scp=84908887461&partnerID=8YFLogxK
U2 - 10.1038/pcan.2014.32
DO - 10.1038/pcan.2014.32
M3 - Journal articles
C2 - 25156059
AN - SCOPUS:84908887461
SN - 1365-7852
VL - 17
SP - 310
EP - 314
JO - Prostate Cancer and Prostatic Diseases
JF - Prostate Cancer and Prostatic Diseases
IS - 4
ER -
